Kirby McInerney LLP is investigating potential claims against the Board of Directors of DUSA Pharmaceuticals, Inc. (“DUSA” or the “Company”) (NASDAQ: DUSA) related to the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Sun Pharmaceutical will commence a tender offer to acquire all of the outstanding common stock of DUSA for $8.00 per share in cash, or approximately $230 million.
The investigation concerns whether the DUSA Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $8.00 per share consideration adequately values DUSA common shares. The average analyst price target for the Company’s shares is $8.33 per share, and at least one analyst has set a price target of $9.50 per share – 17% above the proposed acquisition price.
If you are a DUSA shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at email@example.com, or by telephone at (212) 699-1145 or (888) 529-4787.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmslaw.com.